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cyclosporine, methotrexate and anti-thymocyte globulin (11) . UCB transplant induces GvHD to a lesser degree than MUD transplantation, although UCB hematopoietic recovery is slower, periods and follow-up durations, we only included HSCTs performed after May 1997, the of precocious puberty or hypergonadotropic hypogonadism (low estradiol levels with high well-being, body image, vitality, physical well-being, leisure activities, relationship with limitations due to emotional health, mental health, vitality, bodily pain and general health.
136
Two summary scores are also calculated from the subscales: a physical component score and 137 a mental component score. This is a reliable instrument to assess self-perceived health status 138 in adult survivors of childhood cancer. The French version is well validated.
139
All scores range between 0 and 100, with higher scores indicating better QoL. 
145
Each of the following complications (as defined above) were considered as one late effect:
146
height growth failure (minor or major), overweight (minor or major), low weight, gonadal osteonecrosis, low BMD, diabetes, metabolic syndrome, iron overload and central nervous system complications.
covariates were included in the models: gender, age at diagnosis, age at last visit, history of myeloid leukemia (AML) versus acute lymphoblastic leukemia (ALL)). GvHD was considered as a potential intervening variable, i.e., a variable that is on the causal pathway 156 between the transplant source and health status. Consequently, GvHD was not included in the 157 model (26) . Adjusted odds ratio (OR) and risk of having one type of late effect (including 158 95% confidence intervals) were estimated. Adjusted multiple linear regression models were 159 generated to explore the link between the long-term QoL scores and donor type with the same 160 covariates. Each model is presented with its standardized β coefficient, which measures the 161 strength of the effect of graft type on the QoL dimension score.
162
The SF-36 mean scores reported by adult patients were compared with those obtained from 163 age-and sex-matched French control subjects, using the paired Student's t-test (27) .
164
Statistical significance was defined as p<0.05.
165

RESULTS
166
Patient characteristics
167
A total of 314 patients fulfilled all selection criteria and were included in the analysis.
168
The patient characteristics are summarized in Table 1 . One hundred twenty-seven patients had 169 received stem cells from a SD (40.5%), 99 from a MUD (31.5%) and 88 from unrelated UCB 170 (28.0%). The mean follow-up duration from diagnosis and HSCT to last L.E.A. visit were 7.7±0.2 and 6.2±0.2 years, respectively. The mean age at acute leukemia diagnosis was 7.5±0.3 years; UCB recipients were significantly younger at diagnosis (p=0.02). As expected, the percentage of patients who relapsed before HSCT was significantly higher in the MUD were in first hematologic complete remission at the time of transplantation, compared with patients more often received an alternative donor type (MUD or UCB) (p=0.009).The 
196
The occurrence of each side effect for each group is outlined in Table 2 . The patients 197 treated using SD transplant were considered the reference group for all comparisons. The multivariate analysis indicated that donor type did not have an impact on most sequelae. The adolescents of the SD group reported a significantly better 'school work' mean score than burden of late effects in a multivariate analysis, although only two patients had received UCB survivors had a significantly elevated risk of adverse health-related outcomes, and unrelated
252
HSCT recipients were at greatest risk (15) . Another study involving a cohort of 463 adults 253 and children has reported a significantly higher cumulative incidence of extensive GvHD, 254 cataracts and bone necrosis at 12 years after MUD, compared with SD transplants (16) . To 255 our knowledge, the health status of long-term survivors after UCB transplant has never been 256 described. A few studies have reported late complications after HSCT during childhood, in 257 which some patients had received UCB transplantation. However, no comparison between the 258 donor source was performed, and the cohorts included a very limited proportion of UCB 259 recipients: between 1.2% (14) and 5% (29) .
260
The absolute number of late effects per patient is not a sufficient data point to 261 comprehensively describe health status, as the burden of each late effect may markedly vary.
262
Consequently, in this study we described the risks of specific late effects with respect to stem 263 cell sources. Only two late effects were significantly associated with donor type: including GvHD and its treatments (36, 37) . Significant GvHD occurred more frequently 278 following MUD transplantation compared with the two other groups. However, our data do 279 not support this explanation as we were unable to demonstrate a significant effect of GvHD 280 on major growth failure in our cohort (data not shown).
281
To evaluate QoL, we used self-reported questionnaires for adults, children and 282 adolescents as well as parent-reported questionnaires for patients less than 18 years of age.
283
We found comparable results among the three study groups for all composite scores. This 288 reports studying QoL have found similar results regardless of treatment or health condition, 289 thus suggesting that suffering from acute leukemia may also play a role (27, 38) . We 290 acknowledge that the observed differences in the physical and mental composite scores, albeit 291 statistically significant, were relatively small and their clinical relevance must be thus 292 interpreted with caution. Others studies showed that cGvHD is the major contributor to 293 reduced QoL after HSCT (6, 39) . In our study, significant GvHD incidence was statistically 294 higher among recipients of MUD grafts although QoL was similar. This is perhaps due to the 295 fact that QoL scores reported in our study are the most recent measure for each patient and 296 that survivors with resolved cGvHD may have a comparable long-term QoL to those never diagnosed with cGvHD (39, 40) . Data concerning the impact of donor type on QoL are very long follow-up of transplant patients is recommended regardless of the donor type. 
